

PatientID: HDR11

Okitobba 06, 2023

### Color Code

■ HR: High-Level Resistance    ■ PLR: Potential Low-Level Resistance  
■ LR: Low-Level Resistance    ■ IR: Intermediate Resistance  
■ S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
PI	ATV	LR	V82A
	DRV	S	
	FPV	LR	
	IDV	IR	
	LPV	IR	
	NFV	IR	
	SQV	LR	
	TPV	S	
NRTI	ABC	HR	M41L;K70E;Q151L;L210W;T215I
	AZT	HR	
	D4T	HR	
	DDI	HR	
	FTC	LR	
	LMV	LR	
	TDF	IR	
NNRTI	DOR	HR	G190E;K101H;K103N
	EFV	HR	
	ETR	IR	
	NVP	HR	
	RPV	HR	
INSTI	BIC	IR	R263K
	CAB	IR	
	DTG	IR	
	EVG	IR	
	RAL	LR	

## Appendix

### Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
<b>PI</b>	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
	IDV	Indinavir
	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
<b>NRTI</b>	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
<b>NNRTI</b>	DOR	Doravirine
	EFV	Efavirenz
	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
<b>INSTI</b>	BIC	Bictegravir
	CAB	Cabotegravir
	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

### Comments

DRUG.CLASS	COMMENTS
<b>PI</b>	V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It is associated with reduced susceptibility to LPV and to a lesser extent ATV. It increases DRV susceptibility.
	K70/E/Q/N/T/S/G cause low-level resistance to ABC and TDF.
	L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and intermediate resistance to ABC and TDF.
	M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.
	Q151M causes intermediate/high-level resistance to AZT and ABC, and low-level resistance to TDF, 3TC and FTC. In combination with two or more accessory mutations at positions 62, 75, 77, and 116, it confers high-level resistance to AZT and ABC and intermediate resistance to TDF, 3TC and FTC. Q151L is an extremely rare transitional mutation that may precede the emergence of the Q151M.

**NRTI**

	T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once been infected with a virus containing T215Y/F.
<b>NNRTI</b>	G190E is an uncommon non-polymorphic mutation associated with reduced replication capacity that confers intermediate to high-level resistance to each of the NNRTIs. G190Q is a rare NNRTI-selected mutation that confers high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.
	K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, it contributes reduces susceptibility to these NNRTIs.
	K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
<b>INSTI</b>	R263K is a nonpolymorphic mutation selected in vitro by EVG, DTG, BIC, and CAB. It occurs in a high proportion of persons who develop VF and emergent HIVDR while receiving DTG. Alone, it reduces DTG, BIC, and CAB susceptibility about 2-fold.